|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 47, 2055-2063, September 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology
,











* Institute of Cardiovascular Research, Nanhua University Medical School, Hengyang, Hunan 421001, China
Department of Biochemistry and Molecular Biology, Nanhua University School of Life Sciences and Technology, Hengyang, Hunan 421001, China
Function Laboratory Center, Nanhua University Medical School, Hengyang, Hunan 421001, China
** Institute of Pharmacy and Pharmacology, Nanhua University, Hengyang, Hunan 421001, China

Department of Operative Surgery, Nanhua University Medical School, Hengyang, Hunan 421001, China

Research and Development, Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan
Published, JLR Papers in Press, June 28, 2006.
1 To whom correspondence should be addressed: e-mail wdy20012001{at}yahoo.com
It is widely believed that high density lipoprotein-cholesterol (HDL-C) functions to transport cholesterol from peripheral cells to the liver by reverse cholesterol transport (RCT), a pathway that may protect against atherosclerosis by clearing excess cholesterol from arterial cells. A cellular ATP binding cassette transporter called ABCA1 mediates the first step of RCT. NO-1886 has been proven to be highly effective at increasing HDL-C and reducing atherosclerosis. However, the mechanism of atherosclerosis inhibition for NO-1886 is not fully understood. In this study, the effects of NO-1886 on ABCA1 were investigated in high-fat/high-sucrose/high-cholesterol-fed Chinese Bama minipigs. Administration of NO-1886 (0.1 g/kg body weight/day) in the diet for 5 months significantly reduced atherosclerosis lesions and significantly increased plasma HDL-C and apolipoprotein A-I levels. The mRNA and protein levels of ABCA1 in the liver, retroperitoneal adipose tissue, and aorta were increased by NO-1886 as well. Multivariate linear regression analysis showed that the levels of LPL in plasma and the levels of ABCA1 in aorta were independently associated with the atherosclerotic lesion area. In addition, NO-1886 upregulated liver X receptor
and affected the expression of scavenger receptor class B type I in the liver. These results demonstrate that the mechanism of atherosclerosis inhibition for NO-1886 is associated with its effect on ABCA1.
Supplementary key words liver X receptor
scavenger receptor class B type I [4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]phosphonic acid diethyl ester
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |